IceCure Secures China Patent for Cryogen Flow Control, Enhancing Cryoablation Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy ICCM?
Source: PRnewswire
- Patent Approval: IceCure has received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its cryogen flow control technology related to the next-generation XSense™ cryoablation system, marking a total of 55 patents granted globally, which strengthens its market position.
- Technological Innovation: The new patent enhances the efficacy and tissue safety of cryoablation procedures through precise temperature control, utilizing sensor data to regulate cryogen flow, ensuring the desired temperature is maintained at the distal tip of catheters and probes, significantly improving treatment effectiveness.
- Market Prospects: The ProSense® Cryoablation System has received FDA marketing authorization for the local treatment of low-risk breast cancer, becoming the first medical device approved for women aged 70 and older, which is expected to drive market share growth in this segment.
- Global Expansion: IceCure's innovative technology has not only gained regulatory approval in China but also secured a patent in Japan, with applications pending in the European Union and the U.S., showcasing its potential for global market expansion and strategic significance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.592
Low
3.00
Averages
3.00
High
3.00
Current: 0.592
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Releases ProSense® Kidney Cancer Treatment Data
- Clinical Trial Results: Final data from the ICESECRET trial indicates an 88.7% recurrence-free rate for ProSense® in treating small renal masses, demonstrating its safety and efficacy as a minimally invasive treatment option, addressing the growing need for kidney cancer therapies.
- Growing Market Demand: With an estimated 400,000 new kidney cancer cases globally, including over 80,000 in the U.S., there is an urgent need for alternatives to kidney-preserving surgery, which ProSense® effectively addresses.
- Regulatory Approval Status: ProSense® has received regulatory approval in key markets including the U.S. and Europe for treating both benign and malignant kidney tumors, enhancing its competitive position and market potential.
- Technological Advantages: Utilizing liquid nitrogen for tumor cryoablation, ProSense® accelerates patient recovery and reduces surgical risks, providing an effective treatment option for patients ineligible for surgery, aligning with the current healthcare industry's shift towards minimally invasive technologies.
See More
Alabama's First Breast Cancer Cryoablation Center Opens
- Technology Introduction: Thomas Hospital, Alabama's largest non-governmental healthcare system, has successfully introduced the ProSense® system, becoming the first facility in the state to offer breast cancer cryoablation treatment, which is expected to provide advanced treatment options for local women.
- FDA Approval Impact: The ProSense® system received FDA clearance in October 2025 for the local treatment of low-risk breast cancer, and the hospital's purchase reflects a growing interest in this technology, potentially leading to more installations in the future.
- Patient Selection and Services: Breast surgeon Dr. Katelin Holmes will oversee patient selection, with treatments expected to commence this month, marking a significant advancement in breast care in Alabama and enhancing the hospital's service capabilities.
- Philanthropic Support: The purchase was funded by the Thomas Hospital Foundation, highlighting the role of local philanthropy in advancing medical technology and aiming to provide innovative and compassionate care to the community.
See More
IceCure's ProSense® System Receives FDA Approval for Breast Cancer Treatment
- FDA Approval: IceCure Medical's ProSense® system has received FDA marketing authorization, becoming the first device for local treatment of low-risk breast cancer in women aged 70 and above, marking a significant advancement in non-surgical treatment options that is expected to boost market demand and company revenue.
- New Medical Service: Shero Imaging in Missouri is the first clinic to offer ProSense® breast cancer cryoablation, further expanding IceCure's market reach and likely attracting more patients seeking minimally invasive treatments, thereby enhancing the company's competitive position in the region.
- Technological Advantage: The ProSense® system utilizes liquid nitrogen to create large lethal zones, effectively destroying benign and malignant tumors while accelerating recovery and reducing surgical risks, which is expected to drive adoption of this technology among medical institutions and promote IceCure's market penetration.
- Industry Recognition: Dr. Tish Singer, founder of Shero Imaging, emphasized that the ProSense® system will make breast cancer cryoablation more accessible, enhancing treatment options for patients and reflecting IceCure's leadership in innovative medical technology.
See More
IceCure Medical CFO Ronen Tsimerman Resigns
- Executive Change: IceCure Medical announced the resignation of CFO Ronen Tsimerman, who will remain in his position until a successor is appointed, which may have a short-term impact on the company's financial management and investor confidence.
- Succession Planning: The company has not disclosed any candidates to replace Tsimerman, and the lack of a clear succession plan could raise concerns in the market regarding the company's future financial strategy, potentially affecting shareholder trust in corporate governance.
- Financial Transparency: Tsimerman's resignation may trigger questions about the company's financial transparency, especially ahead of the upcoming Q3 2025 earnings report, leading investors to adopt a cautious stance regarding the company's future financial performance.
- Market Reaction Anticipation: The executive transition may cause fluctuations in IceCure Medical's stock price, particularly given the absence of a successor announcement, which could lead investors to question the company's stability.
See More
IceCure Medical CFO Ronen Tsimerman Resigns
- CFO Resignation: IceCure Medical's CFO Ronen Tsimerman has announced his resignation to pursue new opportunities, although he will remain in his role until a successor is appointed, highlighting the company's commitment to leadership stability during the transition.
- Leadership Achievements: During his nearly decade-long tenure, Tsimerman's financial and operational leadership enabled IceCure to successfully list on Nasdaq and secure funding for the ICE3 study, the largest of its kind in cryoablation, marking significant milestones in the medical technology sector.
- FDA Approval: The ProSense® cryoablation system has received FDA marketing authorization, becoming the only device in the U.S. for treating low-risk breast cancer, indicating IceCure's leadership in innovative medical solutions, which may attract increased investor interest.
- Future Outlook: The company is actively searching for a new CFO and has identified several candidates with substantial experience, demonstrating IceCure's focus on future leadership and commitment to ongoing innovation.
See More
IceCure Medical CFO Ronen Tsimerman to Depart After Nearly a Decade
- CFO Departure Announcement: IceCure Medical has announced that CFO Ronen Tsimerman will continue in his role until a successor is appointed, ensuring a smooth transition in financial leadership despite his decision to pursue new opportunities.
- Leadership Achievements: During his tenure, Tsimerman successfully led the company to its Nasdaq listing and secured funding for the ICE3 study, the largest clinical trial in the cryoablation field, marking significant milestones in the company's medical technology journey.
- FDA-Approved Product: The ProSense® cryoablation system is the first FDA-approved device for treating low-risk breast cancer, providing a non-surgical treatment option for women aged 70 and above, significantly enhancing patient convenience and safety in treatment.
- Future Leadership Transition: IceCure Medical has initiated a search for a new CFO and has identified several candidates with experience in commercializing disruptive technologies, which is expected to positively impact the company's future financial strategy and operations.
See More
IceCure Medical Releases ProSense® Kidney Cancer Treatment Data
- Clinical Trial Results: Final data from the ICESECRET trial indicates an 88.7% recurrence-free rate for ProSense® in treating small renal masses, demonstrating its safety and efficacy as a minimally invasive treatment option, addressing the growing need for kidney cancer therapies.
- Growing Market Demand: With an estimated 400,000 new kidney cancer cases globally, including over 80,000 in the U.S., there is an urgent need for alternatives to kidney-preserving surgery, which ProSense® effectively addresses.
- Regulatory Approval Status: ProSense® has received regulatory approval in key markets including the U.S. and Europe for treating both benign and malignant kidney tumors, enhancing its competitive position and market potential.
- Technological Advantages: Utilizing liquid nitrogen for tumor cryoablation, ProSense® accelerates patient recovery and reduces surgical risks, providing an effective treatment option for patients ineligible for surgery, aligning with the current healthcare industry's shift towards minimally invasive technologies.
See More
Alabama's First Breast Cancer Cryoablation Center Opens
- Technology Introduction: Thomas Hospital, Alabama's largest non-governmental healthcare system, has successfully introduced the ProSense® system, becoming the first facility in the state to offer breast cancer cryoablation treatment, which is expected to provide advanced treatment options for local women.
- FDA Approval Impact: The ProSense® system received FDA clearance in October 2025 for the local treatment of low-risk breast cancer, and the hospital's purchase reflects a growing interest in this technology, potentially leading to more installations in the future.
- Patient Selection and Services: Breast surgeon Dr. Katelin Holmes will oversee patient selection, with treatments expected to commence this month, marking a significant advancement in breast care in Alabama and enhancing the hospital's service capabilities.
- Philanthropic Support: The purchase was funded by the Thomas Hospital Foundation, highlighting the role of local philanthropy in advancing medical technology and aiming to provide innovative and compassionate care to the community.
See More
IceCure's ProSense® System Receives FDA Approval for Breast Cancer Treatment
- FDA Approval: IceCure Medical's ProSense® system has received FDA marketing authorization, becoming the first device for local treatment of low-risk breast cancer in women aged 70 and above, marking a significant advancement in non-surgical treatment options that is expected to boost market demand and company revenue.
- New Medical Service: Shero Imaging in Missouri is the first clinic to offer ProSense® breast cancer cryoablation, further expanding IceCure's market reach and likely attracting more patients seeking minimally invasive treatments, thereby enhancing the company's competitive position in the region.
- Technological Advantage: The ProSense® system utilizes liquid nitrogen to create large lethal zones, effectively destroying benign and malignant tumors while accelerating recovery and reducing surgical risks, which is expected to drive adoption of this technology among medical institutions and promote IceCure's market penetration.
- Industry Recognition: Dr. Tish Singer, founder of Shero Imaging, emphasized that the ProSense® system will make breast cancer cryoablation more accessible, enhancing treatment options for patients and reflecting IceCure's leadership in innovative medical technology.
See More
IceCure Medical CFO Ronen Tsimerman Resigns
- Executive Change: IceCure Medical announced the resignation of CFO Ronen Tsimerman, who will remain in his position until a successor is appointed, which may have a short-term impact on the company's financial management and investor confidence.
- Succession Planning: The company has not disclosed any candidates to replace Tsimerman, and the lack of a clear succession plan could raise concerns in the market regarding the company's future financial strategy, potentially affecting shareholder trust in corporate governance.
- Financial Transparency: Tsimerman's resignation may trigger questions about the company's financial transparency, especially ahead of the upcoming Q3 2025 earnings report, leading investors to adopt a cautious stance regarding the company's future financial performance.
- Market Reaction Anticipation: The executive transition may cause fluctuations in IceCure Medical's stock price, particularly given the absence of a successor announcement, which could lead investors to question the company's stability.
See More
IceCure Medical CFO Ronen Tsimerman Resigns
- CFO Resignation: IceCure Medical's CFO Ronen Tsimerman has announced his resignation to pursue new opportunities, although he will remain in his role until a successor is appointed, highlighting the company's commitment to leadership stability during the transition.
- Leadership Achievements: During his nearly decade-long tenure, Tsimerman's financial and operational leadership enabled IceCure to successfully list on Nasdaq and secure funding for the ICE3 study, the largest of its kind in cryoablation, marking significant milestones in the medical technology sector.
- FDA Approval: The ProSense® cryoablation system has received FDA marketing authorization, becoming the only device in the U.S. for treating low-risk breast cancer, indicating IceCure's leadership in innovative medical solutions, which may attract increased investor interest.
- Future Outlook: The company is actively searching for a new CFO and has identified several candidates with substantial experience, demonstrating IceCure's focus on future leadership and commitment to ongoing innovation.
See More
IceCure Medical CFO Ronen Tsimerman to Depart After Nearly a Decade
- CFO Departure Announcement: IceCure Medical has announced that CFO Ronen Tsimerman will continue in his role until a successor is appointed, ensuring a smooth transition in financial leadership despite his decision to pursue new opportunities.
- Leadership Achievements: During his tenure, Tsimerman successfully led the company to its Nasdaq listing and secured funding for the ICE3 study, the largest clinical trial in the cryoablation field, marking significant milestones in the company's medical technology journey.
- FDA-Approved Product: The ProSense® cryoablation system is the first FDA-approved device for treating low-risk breast cancer, providing a non-surgical treatment option for women aged 70 and above, significantly enhancing patient convenience and safety in treatment.
- Future Leadership Transition: IceCure Medical has initiated a search for a new CFO and has identified several candidates with experience in commercializing disruptive technologies, which is expected to positively impact the company's future financial strategy and operations.
See More
